|1.||Vaali, K: 1 article (05/2010)|
|2.||Aasen, T B: 1 article (05/2010)|
|3.||Van Do, T: 1 article (05/2010)|
|4.||Elsayed, S: 1 article (05/2010)|
|5.||Aardal, N P: 1 article (05/2010)|
|6.||Sun, L-Z: 1 article (05/2010)|
|7.||Florvaag, E: 1 article (05/2010)|
|8.||Shiku, Hiroshi: 1 article (11/2003)|
|9.||Aota, Takumi: 1 article (11/2003)|
|10.||Miyahara, Yoshihiro: 1 article (11/2003)|
11/21/2003 - "However, only mice immunized with HER2 (16-30) and HER2 (63-71), but not with a tumor-unrelated OVA (323-339) and HER2 (63-71), showed in vivo eradication of CMS5mHE tumor cells expressing HER2 but not OVA. "
11/21/2003 - "Conversely, both HER2 (16-30) and OVA (323-339) Th epitopes were equally effective in inducing the eradication of CMS5mHEOVA tumor cells which express HER2 as well as OVA. "
05/01/1999 - "However, we have found that treatment of A20-HL murine B lymphoma cells with CT severely inhibits the presentation of ovalbumin (OVA) to cells of the T cell clone 42-6A specific for OVA(323-339)/I-Ad, whereas it does not affect the presentation of OVA(323-339) peptide. "
10/01/2002 - "Rev.A was assessed for its ability to regulate antigen (Ag) presentation by A20-HL B lymphoma cells bearing trinitrophenyl (TNP)-specific surface IgM (sIgM) to cloned T cells specific for OVA(323-339)/I-Ad. "
04/01/1999 - "Irradiation of A20.2J mouse B-lymphoma cells enhanced their antigen-presenting ability to induce interleukin-2 (IL-2) production by 42-6A T cells specific for ovalbumin (OVA)323-339/I-Ad. "
10/01/2002 - "OVA(323-339):I-A complexes were formed from OVA within 10 min with B6D2F1 macrophages but not until 20 min with C57BL/6 or DBA/2 macrophages, and OVA processing was more resistant to inhibition of late endocytic function by hypothermia (18 degrees C) in B6D2F1 than C57BL/6 or DBA/2 macrophages. "
|5.||Food Hypersensitivity (Food Allergy)
|5.||Immunoglobulin M (IgM)
|7.||Eosine Yellowish-(YS) (Eosin)